What question did this study set out to answer?

To assess the efficacy and safety of dose-escalated simultaneous integrated boost radiotherapy compared with standard radiotherapy regimens in patients with early breast cancer.

June 1, 2023The LancetOpen Access

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

View Full Paper

Ask AI

Bookmark

To assess the efficacy and safety of dose-escalated simultaneous integrated boost radiotherapy compared with standard radiotherapy regimens in patients with early breast cancer.
Multicenter, phase 3, open-label, non-inferiority randomized controlled trial (IMPORT HIGH).
Patients with early breast cancer were randomly assigned to test dose-escalated simultaneous integrated boost radiation against standard treatment strategies.
The trial evaluated primary outcomes including local tumor control and normal tissue toxicity using dose-escalated radiation delivery.
Treatment efficacy and safety profiles were characterized across participating centers to assess non-inferiority criteria.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Randomized noninferiority trial evaluates dose-escalated simultaneous integrated boost radiotherapy in early breast cancer, indicating potential treatment optimization.

Abstract

Cancer Research UK.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Coles et al. (2023) studied this question.

synapsesocial.com/papers/69dfedb3915fa0495361525b https://doi.org/10.1016/s0140-6736(23)00619-0

View Full Paper

Ask AI

Bookmark

Implication

Randomized noninferiority trial evaluates dose-escalated simultaneous integrated boost radiotherapy in early breast cancer, indicating potential treatment optimization.

Abstract

Cancer Research UK.

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading